Studies have also analyzed targeted therapies, such as the LETLOB phase II trial, which randomized 92 postmenopausal women with ER+/HER2- breast cancer to receive neoadjuvant letrozole + lapatinib or letrozole + placebo for 6 months. This evidence concerns the gene ESR1 and breast carcinoma.